Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Lilly shares were down 8% in Thursday premarket trading to $826.57. In an interview Thursday morning, Lilly CEO David Ricks ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly said the revision reflects a $1.57 ... related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of ...

Eli Lilly said the revision reflects a $1.57 ... related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. Get top local Connecticut stories delivered to you every ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly's first-quarter results were driven by exceptional sales of its diabetes treatment, Mounjaro, and weight loss drug, Zepbound. Mounjaro achieved $3.84 billion in revenue, a remarkable 113% ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

Eli Lilly on Thursday reported first-quarter ... related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of ...